BTMD

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners' patients, today announced the Company will provide first quarter financial results on Wednesday, May 6, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be avai

S-8 - biote Corp. (0001819253) (Filer)

8-K - biote Corp. (0001819253) (Filer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

DEFA14A - biote Corp. (0001819253) (Filer)

DEF 14A - biote Corp. (0001819253) (Filer)

10-K - biote Corp. (0001819253) (Filer)

8-K - biote Corp. (0001819253) (Filer)

Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue growth in the second half of 2026 Fourth Quarter 2025 Financial Highlights Revenue of $46.4 million Gross profit margin of 68.0% Net income of $2.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the fourth quarter of 2024 Adjusted EBITDA1 of $11.7 million and Adjusted EBITDA margin1 of 25.2% Full Year 2025 Financial Highlights Revenue of $192.2 million

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading innovator advancing the healthspan of patients' lives by providing hormone replacement therapy and healthy aging solutions, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 11, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Fourth Quarter Earnings Call. A replay of the

8-K - biote Corp. (0001819253) (Filer)

10-Q - biote Corp. (0001819253) (Filer)

8-K - biote Corp. (0001819253) (Filer)

Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025 financial guidance Third Quarter 2025 Financial Highlights Revenue of $48.0 million Gross profit margin of 71.8% Net income of $9.2 million and diluted earnings per share attributable to biote Corp. stockholders of $0.22, compared to net income of $12.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.33 in the prior year period Adjusted EBITDA1 of $12.9 million and Adjusted EBITDA margin1 of 26.9% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the heal

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast w

10-Q - biote Corp. (0001819253) (Filer)

B. Riley Securities downgraded biote Corp. from Buy to Neutral and set a new price target of $4.00

8-K - biote Corp. (0001819253) (Filer)

Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights Revenue of $48.9 million Gross profit margin of 71.6% Net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to net loss of $(10.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.21) in the prior year period Adjusted EBITDA1 of $15.2 million and Adjusted EBITDA margin1 of 31.1% Bio

biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Wednesday, August 6, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Second Quarter Earnings Call. A replay of the webcast w

4 - biote Corp. (0001819253) (Issuer)

8-K - biote Corp. (0001819253) (Filer)

biote Corp.(NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has elected Rich Barrera to the Board, effective immediately. "We are pleased to welcome Rich Barrera to Biote's Board of Directors," said Marc Beer, Executive Chairman of Biote. "Rich has a distinguished background as an investment professional, founding Roystone Capital in 2012 and managing investment portfolios for more than 20 years. For the past few years, we've had the pleasure of working with Rich and his team at Roystone, which is one of Biote's top institutional shareholders

8-K - biote Corp. (0001819253) (Filer)